Literature DB >> 16622644

[Systemic therapy of malignant adrenal tumors].

M Horstmann1, A S Merseburger, A Stenzl, M Kuczyk.   

Abstract

Systemic treatment of advanced-stage adrenal malignancies is most often only palliative. Mitotane alone or in combination with other chemotherapeutic agents such as cisplatin, etoposide, and vincristine are established therapeutic concepts for the treatment of metastatic adrenal cancer. Suramin and gossypol are rarely employed. New therapeutic options are tumor vaccination and treatment with antiangiogenic drugs. Metaiodobenzylguanidine as a radiotherapeutic drug or chemotherapeutic combination therapies that include cyclophosphamide, vincristine, and dacarbazine are applied for systemic treatment of malignant pheochromocytomas.. However, the clinical efficacy of the latter regimen needs further evaluation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16622644     DOI: 10.1007/s00120-006-1038-2

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  31 in total

1.  Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.

Authors:  Alfredo Berruti; Massimo Terzolo; Paola Sperone; Anna Pia; Silvia Della Casa; David J Gross; Carlo Carnaghi; Paolo Casali; Francesco Porpiglia; Franco Mantero; Giuseppe Reimondo; Alberto Angeli; Luigi Dogliotti
Journal:  Endocr Relat Cancer       Date:  2005-09       Impact factor: 5.678

Review 2.  Management of patients with adrenal cancer: recommendations of an international consensus conference.

Authors:  D E Schteingart; G M Doherty; P G Gauger; T J Giordano; G D Hammer; M Korobkin; F P Worden
Journal:  Endocr Relat Cancer       Date:  2005-09       Impact factor: 5.678

3.  Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer.

Authors:  A A Kasperlik-Załuska; B Migdalska; A Makowska
Journal:  Cancer       Date:  1994-03-01       Impact factor: 6.860

4.  Suramin in adrenal cancer: modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect.

Authors:  R V La Rocca; C A Stein; R Danesi; C A Jamis-Dow; G H Weiss; C E Myers
Journal:  J Clin Endocrinol Metab       Date:  1990-08       Impact factor: 5.958

Review 5.  The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.

Authors:  K C Loh; P A Fitzgerald; K K Matthay; P P Yeo; D C Price
Journal:  J Endocrinol Invest       Date:  1997-12       Impact factor: 4.256

6.  A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.

Authors:  Jame Abraham; Susan Bakke; Ann Rutt; Beverly Meadows; Maria Merino; Richard Alexander; David Schrump; David Bartlett; Peter Choyke; Rob Robey; Elizabeth Hung; Seth M Steinberg; Susan Bates; Tito Fojo
Journal:  Cancer       Date:  2002-05-01       Impact factor: 6.860

7.  Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy.

Authors:  J P Luton; S Cerdas; L Billaud; G Thomas; B Guilhaume; X Bertagna; M H Laudat; A Louvel; Y Chapuis; P Blondeau
Journal:  N Engl J Med       Date:  1990-04-26       Impact factor: 91.245

8.  Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: results from ten years of experience.

Authors:  B Shapiro; J C Sisson; D M Wieland; T J Mangner; S M Zempel; E Mudgett; M D Gross; J E Carey; K R Zasadny; W H Beierwaltes
Journal:  J Nucl Biol Med       Date:  1991 Oct-Dec

9.  The management of benign and malignant pheochromocytoma and abdominal paraganglioma.

Authors:  E Edström Elder; A-L Hjelm Skog; A Höög; B Hamberger
Journal:  Eur J Surg Oncol       Date:  2003-04       Impact factor: 4.424

10.  Favorable response of metastatic adrenocortical carcinoma to etoposide, adriamycin and cisplatin (EAP) chemotherapy. Report of two cases.

Authors:  A Berruti; M Terzolo; P Paccotti; F Veglio; A Pia; L Dogliotti; A Angeli
Journal:  Tumori       Date:  1992-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.